Dataset Information

In Vitro and in Vivo Mechanism of Bone Tumor Inhibition by Selenium-Doped Bone Mineral Nanoparticles.

ABSTRACT: Biocompatible tissue-borne crystalline nanoparticles releasing anticancer therapeutic inorganic elements are intriguing therapeutics holding the promise for both tissue repair and cancer therapy. However, how the therapeutic inorganic elements released from the lattice of such nanoparticles induce tumor inhibition remains unclear. Here we use selenium-doped hydroxyapatite nanoparticles (Se-HANs), which could potentially fill the bone defect generated from bone tumor removal while killing residual tumor cells, as an example to study the mechanism by which selenium released from the lattice of Se-HANs induces apoptosis of bone cancer cells in vitro and inhibits the growth of bone tumors in vivo. We found that Se-HANs induced apoptosis of tumor cells by an inherent caspase-dependent apoptosis pathway synergistically orchestrated with the generation of reactive oxygen species. Such mechanism was further validated by in vivo animal evaluation in which Se-HANs tremendously induced tumor apoptosis to inhibit tumor growth while reducing systemic toxicity. Our work proposes a feasible paradigm toward the design of tissue-repairing inorganic nanoparticles that bear therapeutic ions in the lattice and can release them in vivo for inhibiting tumor formation.

SUBMITTER: Wang Y

PROVIDER: S-EPMC5198771 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

In Vitro and in Vivo Mechanism of Bone Tumor Inhibition by Selenium-Doped Bone Mineral Nanoparticles.

Wang Yifan Y Wang Jianglin J Hao Hang H Cai Mingle M Wang Shiyao S Ma Jun J Li Yan Y Mao Chuanbin C Zhang Shengmin S

ACS nano 20161031 11

Biocompatible tissue-borne crystalline nanoparticles releasing anticancer therapeutic inorganic elements are intriguing therapeutics holding the promise for both tissue repair and cancer therapy. However, how the therapeutic inorganic elements released from the lattice of such nanoparticles induce tumor inhibition remains unclear. Here we use selenium-doped hydroxyapatite nanoparticles (Se-HANs), which could potentially fill the bone defect generated from bone tumor removal while killing residua ...[more]

PMID: 27797178

Similar Datasets

Project description:Background and objectivesExperimental data suggest that trace elements, such as arsenic (As), cadmium (Cd), and selenium (Se) can influence the bone remodeling process. We evaluated the cross-sectional association between As, Cd, and Se biomarkers with bone mineral density (BMD) measured at the calcaneus, in a representative sample of a general population from Spain. As secondary analyses we evaluated the associations of interest in subgroups defined by well-established BMD determinants, and also conducted prospective analysis of osteoporosis-related incident bone fractures restricted to participants older than 50 years-old.MethodsIn N = 1365 Hortega Study participants >20 years-old, urine As and Cd were measured by inductively coupled-plasma mass spectrometry (ICPMS); plasma Se was measured by atomic absorption spectrometry (AAS) with graphite furnace; and BMD at the calcaneus was measured using the Peripheral Instaneuous X-ray Imaging system (PIXI). As levels were corrected for arsenobetaine (Asb) to account for inorganic As exposure.ResultsThe median of total urine As, Asb-corrected urine As, urine Cd, and plasma Se was 61.3, 6.53 and 0.39 μg/g creatinine, and 84.9 μg/L, respectively. In cross-sectional analysis, urine As and Cd were not associated with reduced BMD (T-score < -1 SD). We observed a non-linear dose-response of Se and reduced BMD, showing an inverse association below ~105 μg/L, which became increasingly positive above ~105 μg/L. The evaluated subgroups did not show differential associations. In prospective analysis, while we also observed a U-shape dose-response of Se with the incidence of osteoporosis-related bone fractures, the positive association above ~105 μg/L was markedly stronger, compared to the cross-sectional analysis.ConclusionsOur results support that Se, but not As and Cd, was associated to BMD-related disease. The association of Se and BMD-related disease was non-linear, including a strong positive association with osteoporosis-related bone fractures risk at the higher Se exposure range. Considering the substantial burden of bone loss in elderly populations, additional large prospective studies are needed to confirm the relevance of our findings to bone loss prevention in the population depending on Se exposure levels.

Project description:BackgroundOsteoporosis, characterized by reduced bone mineral density (BMD) increases the risk of all-cause mortality. Assessments of whether dietary selenium intake is related to bone health are scarce, with few relevant studies limited by a small sample size. The aim of the present study was to investigate the association between dietary selenium intake and BMD levels in the National Health and Nutrition Examination Survey (NHANES) database.MethodsWe extracted and aggregated data from 4 cycles of the NHANES [2005-2010, 2013-2014]. Dietary selenium intake was obtained from 24-hour dietary recall interviews. BMD measurement, including the femur, femur neck, trochanter and intertrochanter of the femur, and lumbar spine, was performed using dual-energy X-ray absorptiometry. The multivariable linear regression model for the association between dietary selenium intake and BMD and the generalized additive model (GAM) for the dose-response relationship were used.ResultsA total of 21,939 participants were included. The mean age was 40.68±22.42 years, and 51.28% were male. In the multivariable adjustment model, participants with the highest quintiles of dietary selenium intake (Q5) were associated with increased BMD levels in the total femur (β=0.014, 95% CI: 0.008-0.020, P<0.001), femur neck (β=0.010, 95% CI: 0.004-0.016, P=0.001), trochanter (β=0.011, 95% CI: 0.005-0.017, P<0.001), intertrochanter (β=0.017, 95% CI: 0.010-0.025, P<0.001), and lumbar spine (β=0.013, 95% CI: 0.005-0.020, P<0.001) compared with those in quintile 1 (Q1). The dose-response relationship showed an inverted U-shape relationship between dietary selenium intake and BMD levels (P for nonlinearity <0.05). Participants tended to have increased levels of BMD as the dietary selenium intake increased when dietary selenium was below the turning point, and then a negative relationship was observed when dietary intake was higher than the turning point.ConclusionsOur study indicated that dietary selenium intake exhibited an inverted U-shape trend in relation to BMD levels, which demonstrates the need for selenium status in the body to be considered when discussing the role of dietary selenium intake in BMD. Future studies are needed to confirm these findings and explore the underlying biological mechanism.

Dataset Information

In Vitro and in Vivo Mechanism of Bone Tumor Inhibition by Selenium-Doped Bone Mineral Nanoparticles.

Publications

In Vitro and in Vivo Mechanism of Bone Tumor Inhibition by Selenium-Doped Bone Mineral Nanoparticles.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets